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based survey in seven  
European countries 
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Pedro L Ferreira6, Franco Toscani7, Marjolein Gysels8, Lucas 
Ceulemans9, Steffen T Simon10,11, Joachim Cohen4,5 and Richard 
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Abstract
Background: Health-care costs are growing, with little population-based data about people’s priorities for end-of-life care, to guide 
service development and aid discussions.
Aim: We examined variations in people’s priorities for treatment, care and information across seven European countries.
Design: Telephone survey of a random sample of households; we asked respondents their priorities if ‘faced with a serious illness, 
like cancer, with limited time to live’ and used multivariable logistic regressions to identify associated factors.
Setting/participants: Members of the general public aged ≥16 years residing in England, Flanders, Germany, Italy, the Netherlands, 
Portugal and Spain.
Results: In total, 9344 individuals were interviewed. Most people chose ‘improve quality of life for the time they had left’, ranging 
from 57% (95% confidence interval: 55%–60%, Italy) to 81% (95% confidence interval: 79%–83%, Spain). Only 2% (95% confidence 
interval: 1%–3%, England) to 6% (95% confidence interval: 4%–7%, Flanders) said extending life was most important, and 15% (95% 
confidence interval: 13%–17%, Spain) to 40% (95% confidence interval: 37%–43%, Italy) said quality and extension were equally 
important. Prioritising quality of life was associated with higher education in all countries (odds ratio = 1.3 (Flanders) to 7.9 (Italy)), 
experience of caregiving or bereavement (England, Germany, Portugal), prioritising pain/symptom control over having a positive 
attitude and preferring death in a hospice/palliative care unit. Those prioritising extending life had the highest home death preference 
of all groups. Health status did not affect priorities.
Conclusions: Across all countries, extending life was prioritised by a minority, regardless of health status. Treatment and care needs 
to be reoriented with patient education and palliative care becoming mainstream for serious conditions such as cancer.
Keywords
Decision making, cross-cultural comparison, life extension, palliative care, quality of life
1 King’s College London, Cicely Saunders Institute, Department of 
Palliative Care, Policy and Rehabilitation, London, UK 
2 Interdisciplinary Centre for Palliative Medicine, Munich University 
Hospital, Munich, Germany 
3 EMGO Institute for Health and Care Research, Palliative Care Center 
of Expertise and Department of Public and Occupational Health, VU 
University Medical Center, Amsterdam, the Netherlands 
4End-of-Life Care Research Group, Ghent University, Ghent, Belgium 
5 End-of-Life Care Research Group, Vrije Universiteit Brussel, Brussels, 
Belgium 
6 Centre for Health Studies and Research, University of Coimbra 
(CEISUC), Coimbra, Portugal 
7 Istituto di Ricerca in Medicina Palliativa, Fondazione Lino Maestroni  - 
ONLUS, Cremona, Italy
8 Barcelona Centre for International Health Research (CRESIB  - 
Hospital Clínic), Universitat de Barcelona, Barcelona, Spain 
9Campus Drie Eiken, University of Antwerp, Antwerp, Belgium 
10 Center for Palliative Medicine and Center for Integrative Oncology 
(CIO), University Hospital Cologne, Cologne, Germany
11Institute of Palliative Care (ipac), Oldenburg, Germany 
Corresponding author:
Irene J Higginson, King’s College London, Cicely Saunders Institute, 
Department of Palliative Care, Policy and Rehabilitation, Bessemer 
Road, London SE5 9PJ, UK. 
Email: irene.higginson@kcl.ac.uk
488989 PMJ28210.1177/0269216313488989Palliative MedicineHigginson et al.
2013
Original Article
 at The University of Edinburgh on September 24, 2014pmj.sagepub.comDownloaded from 
102 Palliative Medicine 28(2)
Introduction
Innovations and new treatments mean that intensive 
treatments are increasingly offered in advanced illness. As 
a result, about a quarter of health-care expenditure is 
incurred for people in the last year of life.1,2 The costs of 
cancer treatment and care are predicted to increase in the 
United States to over US$173 billion in 2020 and beyond, 
increasing by 600% in 30 years.3 This rise in costs is ech-
oed in most countries and across many diseases, driven by 
the growing prevalence of cancer and chronic conditions in 
ageing populations and the high costs of new intensive 
treatments. Recent criticism proposes that a shift is needed 
to limit intensive second- and third-line chemotherapies 
with little proven benefit on survival, accompanied by 
change of attitudes and practices.4,5
Intensive treatment in advanced illness is often given 
in the belief that patients and their families wish for sur-
vival to preserve hope. However, what are the actual 
patient and public views? Current evidence is conflicting, 
ranging from 40 out of 95 patients attending a London 
cancer centre believing that they would choose intensive 
treatment for a 3-month increase in survival or symptom 
relief6 to 84% of 147 older adults attending centres in the 
United States, preferring medical care focused on comfort 
rather than focused on extending life.7 Data from specific 
centres are unlikely to represent general opinion and vary 
by setting and question format. While some intensive 
treatments are given primarily for symptom relief, some 
have profound side effects or restrict patients’ interactions 
or activities, affecting quality of life.4,6 To ensure appro-
priate future health-care delivery in the face of rising 
costs, robust information on public priorities and prefer-
ences is pressing. Furthermore, we need to understand how 
priorities are influenced by individual characteristics and 
by country, where cultures, religious beliefs, provision of 
palliative care services and legal frameworks vary.8,9 This 
study aimed to examine citizens’ priorities if faced with a 
serious illness, like cancer, and limited time to live, across 
seven European countries, and to identify overall and 
country-specific influencing factors.
Subjects and methods
This study followed the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) guide-
lines,10 and the completed checklist for cross-sectional 
studies is available online (Table A in supplementary data).
Design and participants
This population-based telephone survey covered England, 
Flanders (the Dutch-speaking part of Belgium), Germany, 
Italy, the Netherlands, Spain and Portugal. These countries 
were chosen as they took part in a European collaborative 
(PRISMA) that had the aim to co-ordinate research into end-
of-life care in cancer.11 Each country/region has between 10 
and 81 million inhabitants, diverse sociodemographic pro-
files and palliative care services9 (Table B in supplementary 
data). Portugal, Italy and Spain have a strong influence of 
the Catholic Church, a common tendency for partial disclo-
sure of diagnosis and low use of advance directives com-
pared to north European countries.12 In Flanders and the 
Netherlands, there is a culture of full disclosure and eutha-
nasia is legal since 2002.13,14 In England, specialist pallia-
tive care services are most strongly established, and there is 
a national end-of-life care strategy aiming to raise public 
awareness and challenge taboos about death.8,15 In Germany, 
there is an attitude of full disclosure regarding diagnosis, 
and non-compliance with advance directives has recently 
become a legal offence.16
Individuals aged ≥16 years residing in a household were 
invited to participate in a computer-assisted telephone inter-
view (CATI) by a random selection of households using ran-
dom digit dialling (RDD). Exclusion criteria were incapacity 
to hear or understand the information and provide informed 
consent (assessed by the interviewers) and poor language 
skills that precluded them from participating in the survey in 
the dominant language in each respective country.
Procedures
To ensure standardisation and high-quality data, we devel-
oped comprehensive manuals and trained 149 interviewers 
(95% native speakers) with experience in telephone sur-
veys on social and health issues to administer our question-
naire. Interviews were conducted from May to December 
2010 with at least four call attempts (at least one made after 
6 p.m. to capture working adults).17
The questionnaire was developed and revised following 
review of studies and questions on preferences and priori-
ties for end-of-life care18 and three consultation rounds of 
individual feedback and group discussions with 27 experts 
who were partners in the study.11 The questionnaire had 28 
questions (available online as supplementary data) and 
could be completed in 15 min on the telephone. It was 
piloted using cognitive interviewing, a well-established 
approach when developing surveys19,20 with a purposeful 
sample of 30 volunteers in England and Germany.21 The 
questionnaire was translated into each country’s dominant 
language by forward translations by two independent native 
speakers, backward professional translation and harmoni-
sation of all versions, following European Organisation for 
Research and Treatment of Cancer (EORTC) translation 
procedures.22 Three questions addressed priorities (Box 1) 
regarding treatment, personal care and information/deci-
sion-making. Other questions included social and demo-
graphic backgrounds (with questions adapted from the 
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European Social Survey9) and also end-of-life experiences. 
Publications on other topics covered by the questionnaire 
are available.17,23–26
Telephone surveys have been helping public health 
research and practice for decades;27 this method was also 
the most cost-effective to obtain a random sample of house-
holds. The interviews were carried out using CATI; this 
involves the use of software that allows the questionnaire to 
be displayed on the screen in a standardised way. 
Households were selected via RDD; telephone numbers 
were generated by adding random numbers to real area 
dialling codes in each country. No quotas (geographic or 
sociodemographic) were applied. The questionnaires were 
piloted over the telephone in all the countries (485 inter-
views in 16 days) to test the feasibility and acceptability of 
methods; no changes were made after piloting.
Ethical approval
King’s College London Research Ethics Committee 
approved the study (ref: BDM/08/09-48). We obtained 
local ethics approvals and notified data protection agencies 
in all participating countries. Participants gave verbal con-
sent to interview and could stop at any time. Local support 
was offered if individuals became distressed, following a 
protocol for managing respondent distress.
Statistical analysis
We described and compared responses using percentages 
with 95% confidence intervals (CIs). We tested for differ-
ences using Mann–Whitney U tests, t-tests, Pearson and 
Cochran–Mantel–Haenszel χ2 tests as appropriate. Logistic 
regression was used to verify the relationship between 
potential explanatory demographic variables and respond-
ent preference at the end of life (dependent variable in 
binary scale, coded as 1 = improve quality of life for the 
time left; 0 = extend life or both equally important). All 
available explanatory variables were forced to stay in the 
model. The overall model fit was assessed by using 
Likelihood ratio test. The Max-rescaled R2 was derived to 
assess the total variation explained by the model. We fitted 
separate models for each individual country. Descriptive 
analyses used SPSS 17 for Windows, modelling analyses 
SAS statistical software, version 9.2. Cases with missing 
data were excluded. Tests were two-tailed and p ≤ 0.05 was 
deemed significant. We aimed for a minimum of 1278 com-
pleted interviews in each country to allow us to detect a 9% 
difference (power = 0.90, significance = 0.05) in prefer-
ences or priorities between groups.17
Results
Response rates and sample characteristics
From 45,242 randomly selected households with a known 
eligible person, 9344 people (21%) agreed to participate in 
the study. The response rate was highest in Germany (29%), 
followed by Portugal (28%), Spain (21%), Italy (21%), 
England (21%), Flanders (16%) and the Netherlands (16%). 
Our samples were broadly representative of each country in 
terms of age, gender and social situation (Table 1), although 
there was a high proportion of women responding. Main 
reasons for refusing to participate were lack of interest 
(59%) and lack of time (17%); further information on 
refusal reasons is available elsewhere.17
Box 1. Questions about treatment, care and information/decision-making priorities in the PRISMA survey. 
1.  When people are faced with a serious illness like cancer with limited time to live, they may have to make difficult 
decisions and prioritise some things over others. In this situation, would it be more important to extend your life or 
to improve the quality of life for the time you had left? READ OUT AND CODE ONLY ONE.
□ To extend life
□ To improve the quality of life for the time you had left
□ Both are equally important
2.  When people are faced with a serious illness like cancer with limited time to live, they may have to make difficult 
decisions and prioritise some things over others. In this situation, how would you order the following four aspects 
by their level of importance to you, the first being the most important (1) and the last being the least important (4)?
Aspects RANK 1 = MOST IMPORTANT/4 = LEAST IMPORTANT
A – Keeping a positive attitude
B – Having pain and discomfort relieved
C – Having practical matters resolved
D – Making sure relatives and friends are not worried or distressed
(Box1 Continued)
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Public priorities for treatment, cancer and 
information
In all countries, the treatment priority was for improving 
the quality of life for the time left rather than extending life 
(Table 2). This ranged from 81% (95% CI: 79–83) in Spain 
to 57% (95% CI: 55–60) in Italy. In all countries, only a 
small proportion wanted to extend life, ranging from 2% 
(95% CI: 1–3) in England to 6% (95% CI: 4–7) in Flanders. 
Overall, one in four respondents thought that extending life 
and quality were equally important; this varied between 
countries from 15% (95% CI: 13–17) in Spain to 40% (95% 
CI: 37–43) in Italy.
Of the four possible care choices, across the seven coun-
tries, having pain and discomfort relieved and keeping a 
positive attitude were equally prioritised the highest (36%, 
95% CI: 35–37), followed by relatives/friends not being 
worried or distressed (20%, 95% CI: 19–21) and practical 
matters resolved (9%, 95% CI: 9–10). However, the prior-
ity of these goals varied by country, with keeping a positive 
attitude rated as highest priority in Flanders, Germany, Italy 
and the Netherlands, and pain and discomfort relieved rated 
highest in England and Portugal. In Italy, 36% (95% CI: 
33–38) chose family/friends not being worried or distressed 
(Table 2).
These personal care choices were significantly associ-
ated with prioritising life extension or life quality. After 
adjusting for country differences, those who prioritised 
extending life were more likely to rank keeping a positive 
attitude and making sure friends and relatives are not dis-
tressed as most important (Table 3). Conversely, those who 
prioritised quality of life were more likely to rank having 
pain and discomfort relieved and having practical matters 
resolved as most important. Home death was the most pre-
ferred option overall (69% of respondents), and it was more 
common in those prioritising extending life (74%) versus 
those choosing quality of life (67%). Preference for hospice 
or palliative care unit was much higher in those choosing 
quality of life (21%) versus those choosing life extension 
(9%) (Table 3). Overall, the highest priorities for informa-
tion and decision-making were almost equal for having as 
much information as wanted (37%, 95% CI: 36–38) and 
dying in the preferred place (36%, 95% CI: 35–37), slightly 
lower was choosing who should make decisions about care 
(29%, 95% CI: 28–30). Germany and the Netherlands 
ranked dying in the preferred place (42% and 41%, respec-
tively) the highest, and Germany ranked having as much 
information as wanted (24%) lowest (Table 2). There was 
no relationship between these options and whether the 
respondent preferred life extension or improving quality of 
life (Table 3).
Factors associated with treatment priorities
Logistic regression analysis found variation between coun-
tries in demographic factors associated with respondents’ 
treatment priority of improving quality of life (Table 4). 
Therefore, it was not appropriate to develop an overall 
model across countries. In England, seven characteristics 
(men, married rather than widowed, living alone, no reli-
gious belief, good financial status, the experience of close 
relative’s death and the experience of caring for a relative in 
the past 5 years) were independently associated with prior-
itising quality of life; while in Germany, only the experi-
ence of caring for a close relative in the past 5 years 
mattered (odds ratio (OR)yes vs no = 1.6; 95% CI: 0.2–2.1). In 
Italy, Portugal and Spain, older age was a significant pre-
dictor of prioritising quality of life. A higher education 
level was associated with prioritising quality of life in all 
countries (ORs range: 1.3–7.9) and reached a statistically 
significant level in Flanders, the Netherlands, Portugal and 
Spain. In all countries, the respondent’s health status or 
country of birth were not independent predictors of treat-
ment priority.
Discussion
Common across all countries was the public’s low priority 
for extending life (less than 6% of respondents) if faced 
with advanced cancer. The most popular priority was qual-
ity of life (57% or more of respondents). The largest varia-
tion between countries was observed in whether respondents 
felt that both quality and life extension were equally impor-
tant, with 40% in Italy compared to 15% in Spain choosing 
this option. The consistent emphasis on quality of life, 
either alone or with life extension, has implications for can-
cer treatment and care. Survival rates remain low even from 
diagnosis for some common cancers (such as lung and pan-
creas), especially when metastatic disease is present.4,28 
Asking patients, soon after diagnosis, about their treatment 
3.  What would matter most to you in the care available? Please choose from the following three aspects the one that 
would matter most to you. And in second place?
•	 Having as much information as you want
•	 Choosing who makes decisions about your care
•	 Dying in the place you want
Box 1. Continued
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Table 2. Priorities in treatment, care goals, information and decision-making.
England  
(N = 1351)
Flanders 
(N = 1269)
Germany 
(N = 1363)
Italy  
(N = 1352)
Netherlands 
(N = 1356)
Portugal 
(N = 1286)
Spain  
(N = 1367)
All countries 
(N = 9344)
Treatment priority: would it be more important to extend your life or to improve the quality of life for the time you had left?
Improve quality of life 65 (63–68) 75 (73–78) 73 (70–75) 57 (55–60) 76 (74–78) 70 (67–72) 81 (79–83) 71 (70–72)
Both equally important 32 (30–35) 19 (17–21) 23 (21–25) 40 (37–43) 20 (18–22) 26 (24–28) 15 (13–17) 25 (24–26)
Extend life 2 (1–3) 6 (4–7) 4 (3–5) 3 (2–4) 4 (3–5) 4 (3–6) 4 (3–5) 4 (3–4)
Care priority: goal was the most important priority of four personal care options
Keeping a positive 
attitude
25 (23–28) 39 (36–41) 37 (35–40) 37 (35–40) 41 (39–44) 38 (35–41) 35 (32–37) 36 (35–37)
Pain and discomfort 
relieved
47 (44–50) 37 (35–40) 32 (30–35) 22 (20–24) 35 (33–38) 45 (42–48) 35 (32–37) 36 (35–37)
Relatives/friends not 
worried or distressed
20 (18–22) 19 (16–21) 17 (15–19) 36 (33–38) 13 (11–15) 12 (10–13) 22 (19–24) 20 (19–21)
Practical matters 
resolved
9 (7–10) 6 (5–8) 14 (12–16) 7 (5–8) 11 (9–13) 7 (6–9) 10 (9–12) 9 (9–10)
Information and decision-making: most important priority of three options
Having as much 
information as you want
36 (33–38) 38 (35–41) 24 (22–27) 41 (38–44) 36 (33–38) 46 (43–49) 38 (36–41) 37 (36–38)
Choosing who makes 
decisions about your 
care
31 (29–34) 24 (22–27) 33 (31–36) 36 (33–39) 25 (22–27) 23 (21–26) 28 (26–31) 29 (28–30)
Dying in the place you 
want
34 (32–37) 38 (36–41) 42 (40–45) 25 (23–27) 41 (38–44) 33 (30–35) 36 (33–39) 36 (35–37)
Values are represented as crude percentages by country (with 95% CI).
Table 3. Relationship between treatment priority (improving quality of life, extending life or both equally important); care, 
information and decision-making preferences; and preferences for place of death, adjusting for differences between countries.
N giving this 
as top priority
Improving 
quality of life (%)
Both equally 
important (%)
Extending 
life (%)
p-value (Cochrane–
Mantel–Hanzel 
chi-squared, df)
Care options given as top prioritya
Having pain and discomfort relieved 3202 37.8 33.4 28.9 <0.001 (28.0, 6)
Keeping a positive attitude 3155 36.0 35.2 40.1 0.008 (17.5, 6)
Making sure relatives and friends are not 
worried or distressed
1716 18.1 23.3 23.7 <0.001 (26.8, 6)
Having practical matters resolved 799 9.3 8.9 8.8 0.003 (19.8, 6)
Information and decision-making options  
chosen as top prioritya
Having as much information as you want 3181 36.5 37.7 38.8 0.65 (2.5, 4)
Dying in the place you want 3054 35.7 34.2 38.3 0.67 (2.4, 4)
Choosing who makes decisions about 
your care
2489 29.0 29.4 23.5 0.15 (6.8, 4)
Preferred place of deathb
Own home or that of family member/
friend
6044 66.5 69.4 73.5 <0.001 (70.2, 12)
Hospice or palliative care unit 1731 20.7 16.9 9.2
Hospital (but not palliative care unit) 566 6.1 6.5 9.2
Nursing home or residential home 195 2.1 2.1 4.3
Other place or do not know 419 4.6 5.1 3.7
df: degree of freedom.
The values given in boldface are significant.
aCochrane–Mantel–Hanzel chi-squared tests (adjusting for between-countries differences) were carried out for each care/information/decision-
making option, with a contingency table of option as first, second and third preference versus treatment priorities. Patterns for second and third 
choices followed those for top priorities and so are not presented.
bSingle chi-squared test of most preferred place of death versus treatment priority.
 at The University of Edinburgh on September 24, 2014pmj.sagepub.comDownloaded from 
Higginson et al. 107
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priorities, in terms of life extension and/or quality, would 
be a valuable first step that could help to optimise treatment 
and care.29 Such an approach could be included in clinical 
guidelines, to standardise practice.
Our results suggest that treatment in cancer and other 
conditions will need to shift focus to greater emphasis on 
life quality improvement. Clinicians will also need honed 
skills in symptom management and communication. 
Patients with advanced disease have on average 11 physical 
symptoms30 and complex psychological symptoms.31 
Patients with advanced disease and their relatives fre-
quently report concerns about communication regarding 
diagnosis and treatment.32,33 Our results found that respond-
ents consistently placed a high priority on information and 
decision-making, irrespective of their wish for life exten-
sion or life quality. Single-country studies in Ireland and 
Italy have found similar priorities.34,35 Discussions regard-
ing prognosis and ending treatment can be especially chal-
lenging,33 especially since there may be an association 
between non-acceptance and feelings of hopelessness, a 
sense of suffering, depression and anxiety, along with dif-
ficulties in social relations.36 Thus, achieving a shift towards 
greater emphasis on quality of life will take considerable 
development, including training, with changes in attitude, 
practice and behaviour.4 Better integration of palliative care 
services might also help to achieve this, along with public 
education, because in many countries awareness about pal-
liative care services is low.34,35,37
As might be expected, those respondents prioritising 
treatment to improve quality of life also more often priori-
tised pain and symptom control and less often keeping a 
positive attitude. However, some associations were coun-
ter-intuitive. Those patients most interested in life exten-
sion had the highest preference for home death. This seems 
paradoxical and may be difficult to achieve in practice. 
Intensive treatments to extend life will make home care and 
subsequently achieving home death difficult because often 
treatment will occur in hospital. However, asking about 
preference for place of death of patients and caregivers,17 
plus rapid response home support services, may enable 
patients to be cared for at home.38,39
A higher education level was consistently associated 
with a greater prioritisation of quality of life. Across 
European countries, high levels of education are associ-
ated with longer life expectancy.40 Consequently, those 
with lower levels of education may place greater empha-
sis on life extension. Alternatively, quality of life may be 
a less common concept for individuals with a lower edu-
cational background, and they are less likely to choose 
something they do not understand. However, our finding 
is the opposite of a Dutch public survey, where respond-
ents with lower educational levels preferred quality over 
length of life.41
Despite consistency in general patterns, there were dif-
ferences between countries and little consistency in the 
influencing factors. The two countries that lie in North 
Europe and have legalised euthanasia, Belgium (Flanders 
part) and the Netherlands, were similar to or higher than 
others in prioritising life extension (although it was still 
low – 6% and 4%, respectively). These countries might 
have been expected to place a high priority on who makes 
decisions about care but in fact were at the lower end of 
prioritising this (only 24% and 25%, respectively) com-
pared to England (31%), Germany (33%) and Italy (35%) 
nor were the factors that influenced treatment choices, apart 
from education, similar across these two countries. The 
three south European countries – Italy, Portugal and Spain 
– have been found in other research to show similar low 
expectations of palliative care service provision,12 but we 
found more differences than similarities between these 
countries. In terms of prioritising life quality alone, Italy 
and Spain lay at opposite ends of the spectrum. Religious 
affiliation was associated with a lower prioritisation of 
quality of life in Spain (and also England and the 
Netherlands), but not Italy or Portugal. The prioritisation of 
decision-making was not similar between these countries 
– indeed the opposite – as Italy and Portugal lay at either 
end of the spectrum of views. The common assumption of 
regional similarities in Southern/Latin European countries 
versus Northern/Anglo-Saxon Europe therefore does not 
do justice to patent differences between countries and pop-
ulations. This has implications when caring for patients 
from different parts of Europe in any country or setting and 
highlights the need for both country-specific and individu-
alised approaches to care.
Our study has several strengths. We believe that it is 
the largest assessment of public priorities for treatment if 
faced with advanced illness to date. The study is across 
seven countries, is population based and used standard 
questions in all countries. However, limitations include 
our response rate – 21%. Response rates to telephone 
health surveys are falling and are often similar to ours, 
affected by technologies such as caller identification27 and 
telemarketing fraud and telephone scams.42 We attempted 
to increase our response rate using recommended 
approaches of interviewer training, establishment of 
researcher credentials, increasing call attempts and tar-
geted call times.43 The representativeness of our sample is 
supported by its similarity to the national populations. 
Although it is possible that they had different views, 
Kristal et al.44 found no difference between the health 
behaviours and attitudes of respondents and non-
respondents to a telephone survey. We do not believe that 
this limitation affects the clear low preference for life 
extension or the associated factors. Unfortunately, we 
could not compare respondents and non-respondents 
(since we randomly selected household numbers).
A further limitation is that treatment, care and informa-
tion choices were based on hypothetical choices. Although 
decisions made in real situations can be different from 
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those proposed in hypothetical situations,45 providing con-
textual information (as in our study) considerably improves 
the agreements between choices made in real and hypothet-
ical situations.45 Furthermore, 50% of our sample had cared 
for a close relative or friend at the end-of-life; 28% 
described their own health as fair, bad or very bad.  In the 
last five years, one in 10 had been diagnosed with a serious 
illness and 70% had experienced bereavement. Thus, many 
of those sampled had direct experience of the scenarios 
considered, which helped to place the scenario in context. 
In no country was health status associated with priorities. 
Experiences of bereavement and illness were more often 
associated with prioritising quality of life rather than exten-
sion. Therefore, patients might prioritise life extension 
even less than the low values found in our study.
In conclusion, in all seven countries, few adults (less 
than 6%) believe that when faced with advanced illness, 
such as cancer, extending life is most important and 57% 
or more prioritised quality of life. Cancer treatment and 
care needs to be reoriented towards these views and 
should address top priorities including providing informa-
tion, dying in place of choice, relief of symptoms and sup-
porting relatives and friends. Future guidelines should 
include these priorities, to enable more appropriate treat-
ment choices for patients. The findings indicate a need in 
cancer care for education and palliative care to become 
mainstream.
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